Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	License agreement	Initial Public Offering	Common Stock	Common Stock License agreement	Common Stock Initial Public Offering	Additional Paid-in Capital	Additional Paid-in Capital License agreement	Additional Paid-in Capital Initial Public Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2020	$ (2,773)						$ 3				$ (2,776)
Beginning Balance, Shares at Dec. 31, 2020				4,759,968
Issuance of common stock	1	$ 4,357		$ 1				$ 4,357
Issuance of common stock, Shares				1,606,815	840,500
Vesting restrictions placed on previously issued and outstanding common stock	(1)						(1)
Vesting restrictions placed on previously issued and outstanding common stock, Shares				(2,332,386)
Vesting of restricted shares, Shares				1,724,989
Stock - based compensation	67						67
Net loss	(102,408)										(102,408)
Ending Balance at Dec. 31, 2021	(100,757)			$ 1			4,426				(105,184)
Ending Balance, Shares at Dec. 31, 2021				6,599,886
Issuance of common stock			$ 209,515			$ 1			$ 209,514
Issuance of common stock, Shares						13,529,750
Conversion of August 2021 Notes and accrued interest into common shares	215,364			$ 1			215,363
Conversion of August 2021 Notes and accrued interest into common shares, Shares				10,672,138
Conversion of Takeda Warrant liability into equity	100,020						100,020
Exercise of Takeda Warrant	1			$ 1
Exercise of Takeda Warrant, Shares				5,883,500
Vesting of restricted shares, Shares				958,777
Stock - based compensation	3,003						3,003
Issuance of common stock under stock purchase plan	173						173
Issuance of common stock under stock purchase plan, Shares				11,986
Pension and other postemployment benefits	(281)									$ (281)
Net loss	(159,809)										(159,809)
Ending Balance at Dec. 31, 2022	$ 267,229			$ 4			$ 532,499			$ (281)	$ (264,993)
Ending Balance, Shares at Dec. 31, 2022				37,656,037